ZACHARIAS DANE: Open Payments
NPI 1124758495 · FARMINGTON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$726 in 48 payments from 21 companies in 2025. Trend: 2023 $463 · 2024 $943 · 2025 $726
Food & beverage: $708Education: $19
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $256 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Novo Nordisk Inc | 3 | $46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 5 | $35 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
Products named: VRAYLAR, UBRELVY, REXULTI, JARDIANCE, GEMTESA, VOQUEZNA, Wegovy, Auvelity.
Industry payments across MO — which companies pay providers there.
